1.10 USD
↗ 0.02 (1.85%)AT CLOSE (11:59 AM EDT)
Inovio Pharmaceuticals, Inc.
INONASDAQ • USD
1.10
↘ 0.00 (0.36%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
1.10
↘ 0.00 (0.36%)
Market: CLOSED
Inovio Pharmaceuticals, Inc. (INO) trades at $1.10 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, INO is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jun 26, 2026.
Open?$1.08
High?$1.12
Low?$1.08
Prev. Close?$1.08
Volume?1.2M
Avg. Volume?1.9M
VWAP?$1.10
Rel. Volume?0.61x
Bid / Ask
Bid?$0.93 × 100
Ask?$1.28 × 100
Spread?$0.35
Midpoint?$1.10
Valuation & Ratios
Market Cap?90.5M
Shares Out?82.3M
Float?68.2M
Float %?99.2%
P/E Ratio?N/A
P/B Ratio?14.91
EPS?-$1.03
Dividend?0.00%
Ex-Dividend?N/A
RelatedMRNA
News
Profile
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Themes
Address
660 W. GERMANTOWN PIKE
PLYMOUTH MEETING, PA 19462
Phone: (858) 410-3134
PLYMOUTH MEETING, PA 19462
Phone: (858) 410-3134
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?23
Short Sent.?19
Piotroski F-Score?0/9Weak
Altman Z-Score?-55.88Distress
Confidence?61%Moderate
Short InterestSqueeze Risk
Short % of Float?23.77%Squeeze Risk
Short Interest?16.2M
Days to Cover?10.8
Free Float68.2M
Avg Daily Volume1.5M
Settlement Date2026-06-15
Financial Health
Current Ratio?1.04Adequate
Quick Ratio?1.04Adequate
Cash Ratio?0.69Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?14.91HIGH▾
Peers50
S&P12
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-1,399.7%WEAK▾
S&P3
ROA?-170.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-83573044
Enterprise Value?$64.2M
Fundamentals ratios updated end of day